Limited Time Offer
Get $1000 towards your
first investment
Start investing in private markets with Linqto – your access to disruptive startups and pre-IPO companies.
*Terms and conditions apply. See details
Cadent Therapeutics, founded in 2017 and headquartered in Cambridge, Massachusetts, is a precision neuroscience company focused on developing innovative medicines to restore cognitive and motor function in patients with serious neurological diseases. The company's approach involves tuning and modulating brain rhythms to address complex neurological conditions.
Since its inception, Cadent Therapeutics has made significant strides in the field of neuroscience, raising a total of $55 million in funding. This financial backing has supported the company's research and development efforts in creating targeted therapies for neurological disorders.
It's important to note that on December 17th, 2020, Cadent Therapeutics was acquired by Novartis, a global pharmaceutical company. This acquisition has likely impacted any potential plans for an initial public offering (IPO) that Cadent Therapeutics may have had.
Given the acquisition by Novartis, it's unlikely that Cadent Therapeutics will pursue an IPO as an independent entity. The company's future directions and strategies are now likely aligned with Novartis's broader pharmaceutical portfolio and business objectives.
For investors interested in the neuroscience and pharmaceutical sectors, it's worth noting that while direct investment in Cadent Therapeutics is no longer possible due to the acquisition, the company's innovative approach and potential contributions to neurological treatments may continue to influence the industry landscape under Novartis's umbrella.
Get $1000 towards your
first investment
*Terms and conditions apply. See details
While Cadent Therapeutics' IPO prospects remain uncertain, investors interested in the biotech sector don't have to wait on the sidelines. At Linqto, we offer members access to interests in promising private companies before they go public. Our platform provides opportunities to invest in potential leaders in the pharmaceutical and biotechnology industries, like Cadent Therapeutics, with lower minimum investments than traditional private equity channels. This allows you to potentially benefit from the growth of innovative companies in the healthcare space before they hit the public markets.
*These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO. The information provided above is based on current online discussions and is not intended as investment advice. Linqto does not endorse or guarantee the accuracy of this information, and we strongly recommend conducting your own research or consulting with a professional advisor before making any investment decisions. Linqto cannot be held liable for any investment outcomes resulting from the use of this information.
